Skip to main content

C7R-GD2.CART cells (IV and ICV infusion)

C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)

  • RegistryNCT04099797
  • PhasePhase 1
  • StatusRecruiting
  • ConditionDiffuse Intrinsic Pontine Glioma
  • SponsorBaylor College of Medicine
How C7R-GD2.CART cells (IV and ICV infusion) worksNCT040997971 min

What the film says

Read the transcript

The deadliest childhood brain tumors, diffuse midline gliomas, carry a surface molecule called GD2. Immune cells engineered to hunt GD2 can find them, but they tire and fade before the job is done.

The idea: give the hunters a built-in supply of the signal that keeps T cells alive.

A child's own T cells get two genes. One is a receptor for GD2. The other, C7R, is a permanently switched-on receptor for interleukin-7, the survival signal T cells normally need from outside.

In the first eleven children there were no dose-limiting side effects, and two of seven gliomas shrank.

GAIL-B, at Texas Children's with Jasia Mahdi and Bilal Omer, now gives the cells into the fluid around the brain. Public record; not medical advice.

Sources behind this film

The drug

What is being tested.

Dose levels administered are by IV infusion followed by ICV infusion. Cycle 1: 20 million cells/m2 delivered IV with lymphodepletion. Cycle 2 (and subsequent cycles): Dose level 1: 5 million cells ICV with lymphodepletion.

To prepare the brain cancer specific GD2-C7R T cells, research staff will take some blood from the patient. The researchers will grow the GD2.C7R T cells by infecting the T cells with a retroviral vector (a special virus that can carry a new gene into cells) containing one gene that can recognize and kill brain cancer cells GD2.CAR and the new gene called C7R that will help these cells survive longer.

After the new genes have been put into the T cells, the cells will be tested to make sure that they kill GD2-positive brain cancer cells. All patients on this study are required to have an Ommaya catheter in place prior to treatment as a precaution and for infusion of the T cells. This is a special catheter that leads to the tumor, the cavity left in the brain after surgical removal of the tumor, or into the fluid-filled space in the brain.

The study

How the trial runs.

In this study, there are two treatment groups called Cohort 1 and Cohort 2. Cohort 1 is for patients with diffuse midline glioma, diffuse intrinsic pontine glioma, medulloblastoma, or another rare high-grade glioma that expresses GD2. Cohort 2 is for patients with a type of cancer called progressive diffuse intrinsic pontine glioma that expresses GD2.

Because there is no standard treatment at this time, patients are asked to volunteer in a gene transfer research study using special immune cells called T cells. T cells are a type of white blood cell that help the body fight infection. This research study combines two different ways of fighting cancer: antibodies and T cells. Both antibodies and T cells have been used to treat cancer patients. They have shown promise but have not been strong enough to cure most patients.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Procurement Inclusion Criteria:
  • Histologically confirmed, GD2-expressing newly diagnosed DMG/HGG (including pontine) or confirmation of H3K27 alteration if sufficient tissue for GD2 staining by IHC is not available. Newly diagnosed is defined as prior to radiographic progression or recurrence.
  • Histologically confirmed, GD2-expressing recurrent, refractory, or progressive DMG/HGG (except pontine) or confirmation of positive H3K27 alteration if sufficient tissue for GD2 staining by IHC is not available.
  • Recurrent, refractory, or progressive high-grade CNS tumor with confirmed GD2-expression. Examples include: medulloblastoma "CNS embryonal tumors, AT/RT, ependymal tumors, diffuse gliomas or glioneuronal tumors.
  • Recurrent, refractory, or progressive pontine HGG with confirmed GD2-expression or H3K27-altered DMG
  • Tumors less than 5 cm in maximum dimension at enrollment

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.